Recruiting
Guillain-Barre syndrome
RecruitingA Study of ANX005 for Patients Recently Diagnosed with Guillain-Barré Syndrome to Evaluate How the Drug Works in the Body and Its Safety
InvestigationalNo placebo
A Study of ANX005 for Patients Recently Diagnosed with Guillain-Barré Syndrome to Evaluate How the Drug Works in the Body and Its Safety
InvestigationalNo placebo
- Disease:Guillain-Barre syndrome
- Substances:Humanised IgG4 monoclonal antibody against C1Q
Countries:
Denmark
Denmark- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Humanised IgG4 monoclonal antibody against C1Q
- Sponsor:Annexon Inc.
